This is a repository copy of *Bayesian Inference for Comorbid Disease Risks Using Marginal Disease Risks and Correlation Information From a Separate Source*.

White Rose Research Online URL for this paper: [http://eprints.whiterose.ac.uk/78431/](http://eprints.whiterose.ac.uk/78431/)

**Article:**

[https://doi.org/10.1177/0272989X10391269](https://doi.org/10.1177/0272989X10391269)

---

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
This is an author produced version of a paper published in Medical Decision Making.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/78431

Published paper

http://dx.doi.org/10.1177/0272989X10391269
Bayesian Inference for Comorbid Disease State Risks Using Marginal Disease Risks and Correlation Information from a Separate Source

Mark Strong¹ and Jeremy E. Oakley²

1. School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK

2. Department of Probability and Statistics, University of Sheffield, Hicks Building, Hounsfield Road, Sheffield, S3 7RH, UK

Funding. MS is supported by a UK Medical Research Council Health Services Research / Health of the Public research training fellowship [grant number G0601721].

Address correspondence to Mark Strong, ScHARR, Regent Court, Sheffield, S1 4DA, UK; email m.strong@sheffield.ac.uk.

Available at http://mdm.sagepub.com/content/31/4/571.

Disclaimer: “This version does not include post-acceptance editing and formatting. Medical Decision Making is not responsible for the quality of the content or presentation of the author-produced accepted version of the manuscript or of any version that a third party derives from it. Readers who wish to access the definitive published version of this manuscript and any ancillary material related to this manuscript (correspondence, corrections, editorials, linked articles, etc.) should go to http://mdm.sagepub.com/. Those who cite this manuscript should cite the published version as it is the official version of record.”
ABSTRACT

Background. Public health interventions are increasingly being evaluated for their cost-effectiveness. Such interventions act ‘upstream’ on the determinants of ill health and therefore may reduce the incidence of several diseases. In this case the risks of the separate diseases are likely to be correlated at the individual level, and considerable comorbidity may be present. An economic evaluation should take this comorbidity into account, but estimates of the risks and intervention effects may only be available separately for each disease. This paper proposes a method for combining marginal disease risks and treatment effects with correlation information from a separate source in order to estimate comorbid disease risks and treatment effects.

Method. A case study is presented based on a physical activity cost-effectiveness model. The correlation between the risk of coronary heart disease, stroke and diabetes is estimated from cross sectional data using a Bayesian multivariate probit model. This information is then combined with disease specific marginal baseline risks and intervention effects to give comorbid disease state risks. The expected numbers of QALYs gained through avoiding the comorbid states is estimated from disease specific utility data under a range of assumptions. Finally, the incremental benefit of physical activity is calculated under these utility assumptions. The difference in effectiveness of the intervention due to its impact on reducing or increasing the disease risk correlations is explored in a sensitivity analysis.

Results. If comorbidity is not taken into account, total benefit is overestimated compared with all scenarios in which the comorbidity is included in the model. The overestimation is greatest when physical activity is assumed to reduce disease state co-occurrence as well as overall disease incidence.
INTRODUCTION

The motivation for this paper is the problem of estimating the risks of comorbid disease states when only single disease risk estimates are available from empirical studies. We initially recognised this difficulty in the context of parametrizing a cost-effectiveness model for a ‘public health’ physical activity promoting intervention that was expected to have an impact on the risk of several different diseases. We expect though that the problem of finding comorbid disease state estimates, and our proposed solution, will be applicable in many different health economic modeling contexts, not just those classified as public health.

Public health interventions are generally directed ‘upstream’ at the determinants of ill health, and as such are commonly expected to have an impact on more than one disease.\textsuperscript{1} An example of an upstream determinant of ill health is an individual’s level of physical activity, with a sedentary lifestyle being associated with a range of diseases, including stroke, diabetes and coronary heart disease (CHD). If we wish to evaluate the cost-effectiveness of a physical activity promoting intervention, we will therefore need to take account of the impact of the intervention on the costs and benefits associated with more than one disease.

The UK National Institute of Health and Clinical Excellence (NICE) has evaluated the cost-effectiveness of physical activity promoting interventions as part of its Public Health Guidance programme.\textsuperscript{2} In the economic model published in support of the physical activity guidance,\textsuperscript{3} four diseases were considered: CHD, stroke, diabetes and colon cancer, and a choice was made to evaluate the incremental costs and benefits of physical activity promoting interventions separately for each disease. The total incremental cost and total incremental benefit of the intervention were then assumed to be the sums, respectively, of the four disease specific incremental costs and benefits. This approach of summing incremental costs and consequences calculated separately for a number of diseases is common to a number of other NICE Public Health guidance economic evaluations,\textsuperscript{4-6} and is attractive because evidence required to inform parameter values in the model is often disease specific. There may be very little data available that relate to the
effectiveness of the intervention in reducing the risk of the comorbid disease states (e.g. CHD and diabetes), or on the costs and consequences of those states.

If we assume that the risks and treatment effects for the single disease states in the above models are marginal risks and treatment effects, then summing the expected population costs and consequences that relate to the impact of the intervention on these marginal risks is equivalent to assuming that, where comorbidity exists, the costs and consequences associated with the separate diseases are additive at the individual level. To give an example, this means that the cost saved when an individual person avoids both coronary heart disease (CHD) and a stroke is assumed to be the same as the sum of the costs saved when one person avoids CHD and another avoids a stroke. Likewise, the benefit gained by that individual is assumed to be equal to the sum of the benefits gained when one person avoids CHD, and another avoids a stroke.

To see why this additive assumption is unlikely to hold for benefits, consider a simple example in which benefits are measured in life-years gained. Assume an intervention has the effect of preventing two diseases, A and B. The average age of death is 60 years for a person with disease A, and 65 years for a person with disease B. Without disease, the average age of death is 75 years. The number of life-years gained is 15 for a person avoiding A, and 10 for a person avoiding B. It is difficult to justify why a person avoiding both A and B would gain 25 years of life.

Secondly, consider an example in which an intervention has an effect on quality of life, but not its length, through its effect on two diseases A and B. Health state utility valuations are used as the measure of quality of life. Let's imagine that disease A is associated with a utility weight of 0.7 and disease B with a utility weight of 0.6, while the state of absence of A and B is associated with a utility weight of 0.9. Calculating the population expected benefit under the additive assumption would be equivalent to assuming that a person who avoids both A and B for one year gains \((0.9 - 0.7) + (0.9 - 0.6) = 0.5\) Quality Adjusted Life Years (QALYs).

There is no inherent justification for these additive assumptions for length and
quality of life. In the first case a better assumption may be that the number of life-years gained when a comorbid state is avoided is the same as the number of life-years gained when avoiding the component disease that has the earliest age of death. In the second case there are again more compelling models for comorbid health state utility weights, both for theoretical reasons, and based on empirical data. A common assumption is that the utility weight for a joint health state is the product of the utility weights for the individual component states. In the same way, costs accruing due to the prevention of multiple diseases are unlikely to be simply additive, and we may envisage a range of more plausible models.

If we do decide to base our analysis on a non-additive assumption regarding the comorbid costs and consequences, we will need to quantify the risks of these comorbid disease states under both the intervention and the baseline comparator, and as stated above it is this requirement that provides the motivation for our paper. In order to estimate comorbid disease state risks we need to know something about the degree of co-occurrence (correlation) between the diseases at an individual level, something that is not obtainable from the disease specific studies that are usually used to inform baseline disease risks and treatment effects.

Given that we may not be able to find direct estimates for the comorbid disease state risks in the intervention and comparator groups, our paper proposes a method for combining estimates of the marginal disease specific baseline risk and treatment effects with information relating to the correlation between disease risks derived from an external source. To illustrate our method we have created a simplified version of the NICE physical activity model as a case study that runs throughout the paper.

CASE STUDY

Our case study is loosely based on the economic model published as part of the NICE physical activity guidance. For simplicity of illustration we restrict ourselves to consider only the incremental benefits (in QALYs) of physical activity (denoted the ‘intervention’) over a sedentary lifestyle (‘baseline’). We also restrict
ourselves to considering the effect of physical activity on three diseases: CHD, stroke and diabetes.

**The ‘marginal’ economic model**

In this section we describe our simplified version of the NICE guidance economic model and the evidence used to inform the parameter values. We call this the ‘marginal’ model since it is parametrized in terms of the marginal disease risks and incremental benefits for the three diseases.

We are interested in the incremental health consequences (in QALYs) of the intervention compared with baseline. The model assumes four disease states: well, CHD, stroke and diabetes. Each state is associated with a population mean utility in QALYs, shown in Table 1. Utilities were derived from data reported in the NICE modeling document.³

<table>
<thead>
<tr>
<th>Disease state</th>
<th>Expected QALYs</th>
<th>(95% CrI)</th>
<th>Distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well (u₀)</td>
<td>23.10</td>
<td>(21.02, 25.18)</td>
<td>Normal</td>
</tr>
<tr>
<td>CHD (u₁)</td>
<td>16.11</td>
<td>(14.56, 17.66)</td>
<td>Normal</td>
</tr>
<tr>
<td>Stroke (u₂)</td>
<td>10.84</td>
<td>(10.05, 11.63)</td>
<td>Normal</td>
</tr>
<tr>
<td>Diabetes (u₃)</td>
<td>20.98</td>
<td>(18.93, 23.02)</td>
<td>Normal</td>
</tr>
</tbody>
</table>

The (baseline) incident risks of CHD, stroke and diabetes in a sedentary population, indexed \( j = 1, \ldots, 3 \), are denoted \( b_j \), and the treatment effects (as relative risks) are denoted \( RR_j \) (see Table 2). Ideally these estimates would be derived from studies conducted in populations that are similar to the population of interest. Given \( b_j \) and \( RR_j \) it is then possible to derive estimates for the risks after the intervention, \( t_j = b_j \times RR_j \), and the absolute risk differences, \( t_j - b_j \) (see Table 3).
Table 2. Baseline risks and treatment effects

<table>
<thead>
<tr>
<th>Disease</th>
<th>Baseline risk</th>
<th>(95% CrI)</th>
<th>Distribution</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD ((b_1))</td>
<td>0.172</td>
<td>((0.139, 0.209))</td>
<td>Normal</td>
<td>Wannamethee(^{21})</td>
</tr>
<tr>
<td>Stroke ((b_2))</td>
<td>0.053</td>
<td>((0.046, 0.060))</td>
<td>Normal</td>
<td>Wolf(^{22})</td>
</tr>
<tr>
<td>Diabetes ((b_3))</td>
<td>0.094</td>
<td>((0.085, 0.104))</td>
<td>Normal</td>
<td>Kriska(^{23})</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disease</th>
<th>Treatment effect</th>
<th>(95% CrI)</th>
<th>Distribution</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD ((RR_1))</td>
<td>0.67</td>
<td>((0.52, 0.86))</td>
<td>Lognormal</td>
<td>Salonen(^{24})</td>
</tr>
<tr>
<td>Stroke ((RR_2))</td>
<td>0.72</td>
<td>((0.37, 1.42))</td>
<td>Lognormal</td>
<td>Herman(^{25})</td>
</tr>
<tr>
<td>Diabetes ((RR_3))</td>
<td>0.71</td>
<td>((0.56, 0.91))</td>
<td>Lognormal</td>
<td>Manson(^{26})</td>
</tr>
</tbody>
</table>

Table 3. Risk after intervention and risk difference

<table>
<thead>
<tr>
<th>Disease</th>
<th>Risk after intervention</th>
<th>(95% CrI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD ((t_1))</td>
<td>0.116</td>
<td>((0.082, 0.158))</td>
</tr>
<tr>
<td>Stroke ((t_2))</td>
<td>0.040</td>
<td>((0.019, 0.076))</td>
</tr>
<tr>
<td>Diabetes ((t_3))</td>
<td>0.067</td>
<td>((0.051, 0.086))</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disease</th>
<th>Absolute risk difference</th>
<th>(95% CrI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD ((t_1 - b_1))</td>
<td>-0.057</td>
<td>((-0.088, -0.023))</td>
</tr>
<tr>
<td>Stroke ((t_2 - b_2))</td>
<td>-0.012</td>
<td>((-0.034, 0.022))</td>
</tr>
<tr>
<td>Diabetes ((t_3 - b_3))</td>
<td>-0.027</td>
<td>((-0.042, -0.009))</td>
</tr>
</tbody>
</table>

The marginal model assumes the overall incremental benefit in QALYs, denoted \(\Delta E\), is

\[
\Delta E = \sum_{j=1}^{3} (t_j - b_j)(u_j - u_0),
\]

(1)

where \(u_j\) is the population mean expected number of QALYs experienced by someone with disease \(j\). Those who are well have an expected number of QALYs of \(u_0\) and \(u_j - u_0\) is therefore the expected number of QALYs ‘lost’ by an individual who has disease \(j\).

Evaluating this model with the parameter values in Tables 1 to 3 leads to an
estimated incremental benefit of 0.602 QALYs. This can be interpreted as an additional 0.602 years of perfect health, or an additional $n \times 0.602$ years of health with a utility weight of $n^{-1}$. Propagating parameter uncertainty through the model using standard Monte Carlo based probabilistic sensitivity analysis with 10,000 samples leads to a 95% credible interval of 0.114 to 1.005 QALYs. For the purposes of the uncertainty analysis we assumed normal distributions for the baseline risks, $b_j$, and benefits in QALYs, $u_j$. For relative risks, $RR_j$, we assumed lognormal distributions since these are ratio measures bounded at zero.

**Problems with the marginal model**

The three disease states CHD, stroke and diabetes are clearly not mutually exclusive since it is possible for an individual to have more than one of these diseases; however, there are no parameters in the model that relate to the risks or utilities of the comorbid states. By evaluating overall incremental benefit via Equation 1 we are implicitly making the assumption that the benefit of avoiding a comorbid state (for example, the state of CHD and diabetes) is the sum of the benefits of avoiding each of the component disease states. If we wish to avoid making this additive assumption we need to estimate the risks and utilities for the complete set of mutually exclusive joint disease states, rather than just the marginal risks and single disease specific utilities.

Given three diseases there are $2^3 = 8$ mutually exclusive joint disease states, including the state of good health. In our example these states are: well, CHD alone, stroke alone, diabetes alone, CHD and stroke, CHD and diabetes, stroke and diabetes, and all three diseases. We refer to this set of eight mutually exclusive disease states as the joint disease states and the parameters that relate to these states are denoted by a superscript ‘$*$’. We refer to the four disease states within this set that comprise more than one disease as the comorbid states.

If we are able to estimate parameters for the joint states, our new model for incremental benefit will be

$$\Delta E^* = \sum_{k=0}^{7} (t_k^* - b_k^*)u_k^*, \quad (2)$$
where $k$ indexes the eight mutually exclusive joint disease states (well, CHD alone, stroke alone, diabetes alone, CHD and stroke, CHD and diabetes, stroke and diabetes, all three diseases), $b_k^*$ is the baseline risk of disease state $k$, $t_k^*$ is the intervention risk of disease $k$; and $u_k^*$ is the expected number of QALYs for an individual in disease state $k$. The disease free state is indexed $k = 0$.

Equation 2 can be written in the same form as Equation 1 by recognizing the following. Because $\sum_{k=0}^7 t_k^* = 1$ and $\sum_{k=0}^7 b_k^* = 1$, this means that $\sum_{k=0}^7 (t_k^* - b_k^*) = 0$, and therefore that $(t_0^* - b_0^*) = -\sum_{k=1}^7 (t_k^* - b_k^*)$. As a result we can write

$$\Delta E^* = \sum_{k=0}^7 (t_k^* - b_k^*)u_k^*,$$

$$= \sum_{k=1}^7 (t_k^* - b_k^*)u_k^* + (t_0^* - b_0^*)u_0^*,$$

$$= \sum_{k=1}^7 (t_k^* - b_k^*)u_k^* - \sum_{k=1}^7 (t_k^* - b_k^*)u_0^*,$$

$$= \sum_{k=1}^7 (t_k^* - b_k^*)(u_k^* - u_0^*).$$

**Estimating the utilities for the joint disease states ($u_k^*$)**

The utility, in QALYs, for a disease state is determined by both length and quality of life. We assume that we do not have empirical evidence that relates to the mean length of life for the comorbid states, and nor do we have quality of life data for the comorbid states. We therefore must model these parameters based on the length and quality of life data for the single diseases.

As regards length of life we assume that the age of death for an individual who has more than one disease is the earliest of the ages of death for the single diseases that make up the individual’s comorbid disease state. As regards quality of life we explore three models, based on theoretical and empirical arguments in the literature.\(^7\,^8\)

**Joint state QALY model 1 - multiplicative.** The quality of life (as measured by an EQ5D utility weight) for each comorbid state is the product of the utility weights
for the single diseases that make up the comorbid state.

*Joint state QALY model 2 - minimum.* The quality of life weight for each comorbid state is the minimum of the utility weights for the single diseases that make up the comorbid state.

*Joint state QALY model 3 - additive decrement.* The reduction in quality of life weight between the well state and each comorbid state is the sum of the utility *decrements* (i.e. the difference in utility weight between well and disease) for the individual diseases that make up the comorbid state.

Note that model 3 differs from the marginal model in that total benefits in QALYs are assumed to be additive under the marginal model, whereas in model 3 the additive decrement assumption applies only to quality of life weights. *Length* of life decrements are not additive under any of the joint state QALY models.

Table 4 shows the estimated utility in QALYs for the eight joint states calculated under these three models.

<table>
<thead>
<tr>
<th></th>
<th>Comorbidity utility assumption</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Multiplicative</td>
<td>Minimal</td>
<td>Additive</td>
<td></td>
</tr>
<tr>
<td>Well ((u_0^*))</td>
<td>23.04 (21.09, 24.96)</td>
<td>23.01 (21.03, 24.89)</td>
<td>23.06 (21.18, 24.97)</td>
<td></td>
</tr>
<tr>
<td>CHD alone ((u_1^*))</td>
<td>16.04 (14.52, 17.51)</td>
<td>16.07 (14.42, 17.54)</td>
<td>16.06 (14.49, 17.56)</td>
<td></td>
</tr>
<tr>
<td>Stroke alone ((u_2^*))</td>
<td>10.82 (10.01, 11.56)</td>
<td>10.81 (10, 11.63)</td>
<td>10.82 (10.02, 11.6)</td>
<td></td>
</tr>
<tr>
<td>DM alone ((u_3^*))</td>
<td>21.02 (19.13, 22.93)</td>
<td>20.95 (18.95, 22.83)</td>
<td>21.04 (19.06, 23.03)</td>
<td></td>
</tr>
<tr>
<td>CHD &amp; stroke ((u_4^*))</td>
<td>9.84 (9.07, 10.61)</td>
<td>10.13 (9.36, 10.93)</td>
<td>8.99 (7.98, 9.95)</td>
<td></td>
</tr>
<tr>
<td>CHD &amp; DM ((u_5^*))</td>
<td>13.63 (12.23, 15.09)</td>
<td>14.23 (12.9, 15.46)</td>
<td>12.14 (10.14, 14.1)</td>
<td></td>
</tr>
<tr>
<td>Stroke &amp; DM ((u_6^*))</td>
<td>10.07 (9.29, 10.8)</td>
<td>10.30 (9.54, 11.03)</td>
<td>9.40 (8.5, 10.39)</td>
<td></td>
</tr>
<tr>
<td>All 3 diseases ((u_7^*))</td>
<td>9.40 (8.7, 10.09)</td>
<td>9.87 (9.1, 10.64)</td>
<td>7.58 (6.39, 8.76)</td>
<td></td>
</tr>
</tbody>
</table>

**Estimating the joint disease risks, \(b_k^*\) and \(t_k^*\)**

We assume that we have estimates of the baseline risks and treatment effects for the three single (marginal) disease states, CHD, stroke and diabetes, that are
relevant to our population (we call this dataset A). We do not have information on
the baseline risks and treatment effects for the comorbid disease states since the
studies we have found are disease specific. However, we do have information from
elsewhere that relates to the correlation between our three diseases in the form of
individual level data from a cross sectional study (we call this dataset B). If the
correlation information in dataset B can be combined with the estimates of the
marginal baseline risks and treatment effects in dataset A then we can estimate
the eight joint disease risks we require.

The presence or absence of the three diseases in dataset B represents correlated
binary data. However, describing correlation between binary variables is not
straightforward. The Pearson correlation coefficient will depend on the popula-
tion proportions of the three diseases, and instead of varying between $-1$ and
$+1$ as it does for continuous data, will lie on a narrowed interval that is not sym-
metric about 0, potentially making interpretation of the measure difficult. Ideally,
we would like a measure of correlation that is independent of the marginal popu-
lation proportions of the three diseases, and that lies between $-1$ and $+1$ for ease
of interpretation.

One solution to this problem is to link the correlated binary outcomes to a latent
variable with a multivariate normal distribution, therefore allowing the corre-
lation structure in the data to be expressed through the covariance matrix of the
multivariate normal distribution. If the covariance matrix is expressed in corre-
lation form, then we have a measure that fulfils both our criteria above. Linking
a binary outcome to an underlying multivariate normal latent variable is an ex-
ample of the use of a multivariate probit model, discussed in detail by Chib and
Greenberg (1998), and by Albert and Chib (1993).

To illustrate the multivariate probit model we first assume that we have data, $y_{ij}$,
on $i = 1, \ldots, n$ individuals, relating to the presence or absence of $j = 1, \ldots, 3$
diseases. The binary data $y_{ij}$ are linked to the latent variable, denoted $z_{ij}$, via
$y_{ij} = \mathcal{I}(z_{ij} > 0)$, where $\mathcal{I}(\cdot)$ is the indicator function, taking value 1 if $z_{ij} > 0$,
and 0 otherwise. The latent variable vector for each individual $i$ is denoted $z_i =
(z_{i1}, z_{i2}, z_{i3})$, and these are assumed to have a tri-variate normal distribution, i.e.
that they are realizations of a random variable, $Z_i$, with $Z_i \sim N_3(\mu, \Sigma)$. Here, $\mu = (\mu_1, \mu_2, \mu_3)$ describes, on the latent continuous scale (i.e. $-\infty$ to $+\infty$), the marginal disease risks in the cross-sectional study population, and the covariance matrix $\Sigma$ models the dependency between the binary disease states. The latent variable $Z_i$ could be envisaged as quantifying an underlying degree of propensity for each disease on a continuous scale. If the propensity for disease $j$ exceeds some threshold, then that disease occurs.

**Estimating $\Sigma$ for our case study**

We have cross sectional data on 18,553 individuals that relate to the presence or absence of CHD, stroke and diabetes. These data come from the Health Survey for England (HSE) 2003. The HSE is a large, annually conducted survey of a representative sample of the population of England that aims to provide information on the health status of the population.

We took a Bayesian approach and estimated the correlation between the risks of CHD, stroke and diabetes from the HSE data using Chib and Greenberg’s multivariate probit model (see Appendix A). Appendix B shows annotated BUGS code that we ran in OpenBUGS 3.0.8. We placed the following weak priors on the mean and correlation parameters: $\mu \sim N_3(0, 10^6I_3)$ and $\Sigma \sim IW(I_3, 3)$, where $I_3$ is the three dimensional identity matrix and $IW$ is the inverse Wishart distribution, parametrized in terms of an inverse scale matrix and a number of degrees of freedom. We ran three Markov chains, each with a different set of initial parameter values. The Brooks-Gelman-Rubin diagnostic suggested adequate convergence after a burn in of 50,000 samples.

The samples from the posterior distribution of the parameters of the correlation matrix, $\Sigma$, were highly autocorrelated. The presence of positive autocorrelation in an MCMC chain increases the number of samples required to achieve some pre-specified level of accuracy in the estimates of the mean and variance of the posterior distribution. This is because each successive iteration in an autocorrelated chain provides a smaller amount of independent information than each
iteration in an uncorrelated chain.

Thinning the chain is sometimes employed to reduce autocorrelation and is appropriate if the size of the sample that can be processed is fixed at some level, usually due to limited computer memory storage. Given a chain of length \( N \), and a thinned sample set of length \( n \) from that chain (i.e. thinning the chain keeping every \( k^{th} \) sample where \( k = \frac{N}{n} \)) it is better to base inference on the thinned sample set of size \( n \), than on \( n \) consecutive samples from the un-thinned chain. However, inferences based on a thinned sample set of size \( n \) will always be less accurate than inferences based on the full un-thinned chain of length \( N \).\(^{17}\)

We generated a total of 250,000 samples from the three MCMC chains after burn-in and estimated means and variances for the parameters of the correlation matrix, \( \Sigma \), using the whole sample set. We then selected every 25th sample (i.e. 10,000 samples in total) for use within the economic model, given that propagating all 250,000 samples through the economic model in a probabilistic sensitivity analysis (described below) would have taken a prohibitively long time. Thinning the chain in this way, rather than simply selecting the first 10,000 samples, reduced the autocorrelation in the sample set used within the economic model and therefore increased the accuracy of the probabilistic sensitivity analysis.

The marginal risks calculated from the HSE dataset were 46 per 1000 for CHD, 20 per 1000 for stroke and 33 per 1000 for diabetes, and the correlations between the disease risks on the latent scale were 0.509 (95% CrI 0.459 to 0.558) for CHD and stroke, 0.441 (95% CrI 0.391 to 0.490) for CHD and diabetes, and 0.400 (95% CrI 0.338 to 0.460) for stroke and diabetes.

**Combining \( \Sigma \) with marginal risks to calculate joint disease state risks**

Once we have estimated \( \Sigma \) we must then combine this correlation information with the marginal disease risks \( b_j \) and \( t_j \) to give the baseline and treated risks \( b_k^* \) and \( t_k^* \) for the \( k = 0, \ldots, 7 \) joint states. There is no closed form analytical solution to this problem, but the simulation based solution described below is straightforward.
The marginal risks \( b_j \) and \( t_j \) are first transformed onto the latent scale via the inverse normal cumulative distribution function, \( \Phi^{-1}(\cdot) \),

\[
\begin{align*}
\mu_{b_j} &= \Phi^{-1}(b_j), \\
\mu_{t_j} &= \Phi^{-1}(t_j).
\end{align*}
\]

To obtain the joint disease risks for baseline we draw a large number \((i = 1, \ldots, m)\) of samples, \( z_i = (z_{i1}, z_{i2}, z_{i3}) \), from the tri-variate \( N_3(\mu_b, \Sigma) \) distribution, where \( \mu_b = (\mu_{b1}, \mu_{b2}, \mu_{b3}) \). These samples are transformed onto the binary scale via the indicator function \( y_{ij} = I(z_{ij} > 0) \) giving a correlated binary dataset with marginal disease risks \( b_j \), and a correlation structure that reflects the individual level disease dependence that we require. The joint risks \( b^*_i \) are obtained from the \( y_{ij} \) via the expressions in Table 5. The eight joint absolute risks for the intervention group \( t^*_i \) are calculated in the same manner. This is done using the same correlation matrix, \( \Sigma \), as for the baseline risks, or using a different correlation matrix if there is evidence to support a different dependence structure after the intervention.

**Table 5. Expressions for calculating joint disease risks**

<table>
<thead>
<tr>
<th>Disease state</th>
<th>Expression for ( b^*_i )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well</td>
<td>( b^*<em>0 = \frac{1}{n} \sum</em>{i=1}^{n} [(1 - y_{i1})(1 - y_{i2})(1 - y_{i3})] )</td>
</tr>
<tr>
<td>CHD alone</td>
<td>( b^*<em>1 = \frac{1}{n} \sum</em>{i=1}^{n} [y_{i1}(1 - y_{i2})(1 - y_{i3})] )</td>
</tr>
<tr>
<td>Stroke alone</td>
<td>( b^*<em>2 = \frac{1}{n} \sum</em>{i=1}^{n} [(1 - y_{i1})y_{i2}(1 - y_{i3})] )</td>
</tr>
<tr>
<td>DM alone</td>
<td>( b^*<em>3 = \frac{1}{n} \sum</em>{i=1}^{n} [(1 - y_{i1})(1 - y_{i2})y_{i3}] )</td>
</tr>
<tr>
<td>CHD and stroke</td>
<td>( b^*<em>4 = \frac{1}{n} \sum</em>{i=1}^{n} [y_{i1}y_{i2}(1 - y_{i3})] )</td>
</tr>
<tr>
<td>CHD and DM</td>
<td>( b^*<em>5 = \frac{1}{n} \sum</em>{i=1}^{n} [y_{i1}(1 - y_{i2})y_{i3}] )</td>
</tr>
<tr>
<td>Stroke and DM</td>
<td>( b^*<em>6 = \frac{1}{n} \sum</em>{i=1}^{n} [(1 - y_{i1})y_{i2}y_{i3}] )</td>
</tr>
<tr>
<td>All 3 diseases</td>
<td>( b^*<em>7 = \frac{1}{n} \sum</em>{i=1}^{n} [y_{i1}y_{i2}y_{i3}] )</td>
</tr>
</tbody>
</table>

Table 6 shows the estimated absolute risk for each joint disease state at baseline (no physical activity) and with physical activity (expressed as numbers of cases per 1000 population) under two assumptions: firstly that disease risks are independent (i.e. that \( \Sigma = I_3 \)), and secondly that the correlation is the same as that in the HSE population.
Table 6. Estimated numbers of cases (per 1000 pop) by joint disease outcome

| Disease state       | Comorbidity utility assumption |  |  |  |  |  |  |  |
|---------------------|-------------------------------|--|---|---|---|---|---|
|                     | At baseline                   |  |  |  |  |  |  |  |
|                     | Independent | Correlated | Difference | Independent | Correlated | Difference |
| Well                | 710.8 | 755.2 | 44.4 | 792.0 | 826.2 | 34.2 |
| CHD alone           | 147.8 | 114.1 | -33.7 | 103.6 | 77.4 | -26.2 |
| Stroke alone        | 39.4 | 19.4 | -20.1 | 33.0 | 16.7 | -16.3 |
| DM alone            | 73.5 | 48.5 | -25.0 | 56.9 | 37.7 | -19.1 |
| CHD and stroke      | 8.2 | 17.7 | 9.5 | 4.3 | 12.6 | 8.3 |
| CHD and DM          | 15.3 | 29.6 | 14.3 | 7.4 | 18.6 | 11.1 |
| Stroke and DM       | 4.1 | 4.8 | 0.7 | 2.4 | 3.6 | 1.2 |
| All 3 diseases      | 0.8 | 10.7 | 9.8 | 0.3 | 7.2 | 6.9 |

The risk of being in either a comorbid state, or in the no disease state, is greater under the correlated risks assumption than under the independence assumption, reflecting the positive correlations in risks between all three marginal disease states.

Calculating incremental benefit under a range of scenarios

We explored a range of scenarios in which we combined different assumptions about disease risk correlation structure with different models for the comorbid disease states utilities.

In the first three scenarios we considered disease risks to be independent, both at baseline and after the intervention. In the second set of three scenarios we considered both baseline and treated risks to be correlated, with the degree of correlation estimated from the HSE data. Because there may be good reasons for assuming different correlation structures in the baseline disease risks and treated risks we wanted to explore two further scenarios. Baseline risks were assumed to have the same correlation structure as that estimated from the HSE data, but treated risks were assumed firstly, to have a higher degree of correlation (by a factor of 10%), and secondly, to have a lesser degree of correlation (by a factor of 10%).

16
For each of the four sets of scenarios we assumed the three models described above for comorbid disease state utilities: multiplicative, minimal and additive. In each of the resulting 12 scenarios we calculated the incremental benefit via Equation 2.

**Probabilistic sensitivity analysis**

In order to conduct a probabilistic sensitivity analysis, uncertainty in the estimates for the baseline risk and treatment effect parameters, as well as for the correlation matrix, \( \Sigma \), must be propagated through the model. Because the joint risk parameters \( b_k \) and \( t_k \) are calculated via simulation, two levels of simulation are required to determine the uncertainty in the model output. See Halpern et al for a discussion of such nested models.\(^{18}\) Samples are drawn from the posterior distributions of the parameters \( u_j, b_j, RR_j \) and \( \Sigma \) in an outer loop, and for each run of the outer loop, the joint risk parameters \( b_k \) and \( t_k \) are estimated through a large number of runs of an inner, nested, loop. For the purposes of our case study we drew 10,000 samples from the outer loop parameters, and based each estimate of \( b_k \) and \( t_k \) on 2,000 inner loop samples.

**Results**

If the benefits of the intervention are calculated separately for each disease and then summed (the marginal approach as taken in the NICE models identified in the introduction,\(^{2,4-6}\)) then the overall incremental benefit calculated via Equation 1 is estimated to be 0.602 (95\% CrI 0.114 to 1.005). This marginal approach overestimates the benefit of the intervention compared with that predicted in all our twelve scenarios (Table 7). The overestimation is largest when the marginal approach is compared with the scenario in which the minimal model was used to estimate utilities of the comorbid states, the baseline risks were correlated, and the correlation in the risks was reduced after the intervention. The overestimation is least in the case where the additive decrement assumption was used for comorbid state utilities, and the disease risks were considered to be independent.
Table 7. Incremental benefits in QALYs (SE)

<table>
<thead>
<tr>
<th></th>
<th>Comorbidity utility assumption</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Additive decrement</td>
<td>Minimal</td>
<td>Multiplicative</td>
<td></td>
</tr>
<tr>
<td>Baseline risks</td>
<td>Treated risks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Independent</td>
<td>Independent</td>
<td>0.590 (0.220)</td>
<td>0.568 (0.218)</td>
<td>0.573 (0.217)</td>
</tr>
<tr>
<td>HSE</td>
<td>HSE</td>
<td>0.565 (0.229)</td>
<td>0.519 (0.216)</td>
<td>0.533 (0.220)</td>
</tr>
<tr>
<td>HSE</td>
<td>HSE+10%</td>
<td>0.573 (0.228)</td>
<td>0.533 (0.215)</td>
<td>0.546 (0.219)</td>
</tr>
<tr>
<td>HSE</td>
<td>HSE−10%</td>
<td>0.558 (0.229)</td>
<td>0.506 (0.216)</td>
<td>0.522 (0.221)</td>
</tr>
</tbody>
</table>

HSE. Correlation structure estimated from the Health Survey for England data.

In general, the overestimation of the marginal approach will be worst when there
is a high degree of positive correlation between disease risks at baseline which
then weakens after the intervention. To see why, consider the following. A large
positive correlation between diseases at baseline implies that many individuals
who are ill will have more than one disease. If, in the intervention group, the
correlation in disease risk is smaller than in the baseline group, then this implies
that the intervention is protective against the comorbid states, and that many
instances of a comorbid disease state would be avoided if the intervention were
to be implemented. Under the marginal model the value of avoiding a comorbid
state is overvalued, primarily due to the unrealistic assumption of additivity of
life years gained, and it is this overvaluation that leads to the overestimation of
incremental benefit.

DISCUSSION

Our analysis suggests that the marginal approach to modeling the impact of an
intervention on multiple diseases is likely to overestimate the overall benefit, unless
benefits really are additive at an individual level. Even if diseases are assumed to
be independent, the marginal approach will still lead to overestimation of benefit
because the marginal approach assumes an additive decrement of length of life as
well as quality of life for comorbid states. Overestimation by the marginal model
will only be avoided if the diseases are mutually exclusive.

The differences between the results of the marginal model and the twelve alternative scenarios we present in our case study are modest. However, even small differences in costs and benefits may be important if the overall cost-effectiveness is close to the decision threshold. This holds even when credible intervals overlap since it is the mean incremental costs and benefits that are of primary importance to the decision maker.¹⁹

The ideal approach to modeling cost-effectiveness in the presence of multiple diseases would be to explicitly include parameters that relate to all the possible joint disease states, and obtain values for these parameters directly from the literature. It would then be entirely correct to sum costs and benefits over these states since they would be mutually exclusive. The difficulty is finding estimates of the baseline risks and treatment effects for the joint states in the literature.

Limitations

Our approach has a number of limitations. Fundamental to the latent variable formulation is the belief that the correlation structure in a multivariate normal continuous variable can, for our purposes, meaningfully model the correlation structure in the multivariate binary disease outcome. Multivariate normality implies that the correlation is independent of the mean marginal disease risks on the latent scale, but this is not true for the binary disease outcomes, where variances and covariances are functions of the mean.

If the latent variable \( Z_i \) is considered to have a physical meaning, in that evidence suggests that each disease state arises when some underlying continuous process exceeds a threshold, then our approach would seem reasonable on these grounds. However, if no such physical interpretation for the latent variable exists, then the variable might be considered instead an artefact, included in order to introduce into the cost-effectiveness model information about the correlation structure in an external data set. In this case it may be necessary to consider carefully whether the marginal risks in the population from which the correlation structure is estimated
are similar enough to those in the studies used to derive the risk estimates in the model, given the dependence between the correlation and mean in multivariate binary data.

In our case study the marginal risks of CHD, stroke and diabetes were estimated as 172 per 1000, 53 per 1000 and 94 per 1000 at baseline (no physical activity), and as 115 per 1000, 38 per 1000 and 67 per 1000 in those who took exercise. Both baseline (no physical activity) and intervention (active) disease risks are somewhat higher in magnitude than the marginal disease risks estimated from the HSE data, which were 46 per 1000 for CHD, 20 per 1000 for stroke and 33 per 1000 for diabetes. Ideally we would estimate the baseline disease risk correlation using data from a sedentary population whose marginal disease risks are as close as possible to the baseline risk estimates we are using to parametrize the economic model. Likewise, intervention disease risk correlations would ideally be estimated using data from an active population with marginal disease risks similar to the intervention group risks used in the economic model.

Lastly, we have been able to estimate the correlation between the disease states in our model from primary data. These data may not always be available, and in this case expert elicitation may be considered as an option for learning about the correlations between disease states. The correlation parameters in our model essentially represent the correlations in underlying risks of disease, each expressed on a continuous scale, and their meaning, at least in a qualitative sense, could be expected to be fairly well understood intuitively. However, eliciting values for the correlation parameters is likely to be difficult, particularly for cases where there are more than two disease states.20

Conclusion

This paper presents one approach to synthesizing information relating to disease risk correlation with marginal risks and treatment effects in order to estimate joint risks and treatment effects in the absence of direct empirical data. The method allows for the determination of the sensitivity of a model output to dif-
ferent assumptions about the correlation between disease risks, and as such has the potential to strengthen the robustness of a prioritization decision.
References


Appendix A - Chib and Greenberg’s method for estimating the correlation matrix, $\Sigma$

We have binary data $y_{ij}$ relating to the presence or absence of $j = 1, \ldots, J$ diseases on $i = 1, \ldots, I$ individuals. We introduce a latent variable $z_{ij}$ that relates to $y_{ij}$ via $y_{ij} = I(z_{ij} > 0)$ where $I(\cdot)$ is the indicator function. We assume $z_i = (z_{i1}, \ldots, z_{ij})$ are realizations of the random variable $Z_i \sim N_f(\mu, \Sigma)$.

The matrix, $\Sigma$, which must be in correlation form to ensure identifiability, can be estimated from data using Bayesian methods. Under the multivariate probit model, proposed by Chib and Greenberg, the likelihood for the data is

$$P(Y_i = y_i|\mu, \Sigma) = \int_{B_{i1}} \cdots \int_{B_{ij}} \frac{1}{\sqrt{(2\pi)^I|\Sigma|}} e^{-\frac{1}{2}(Z_i-\mu)^T\Sigma^{-1}(Z_i-\mu)} dZ_i,$$

with

$$B_{ij} = \begin{cases} (-\infty, 0) & \text{if } y_{ij} = 0, \\ [0, \infty) & \text{if } y_{ij} = 1. \end{cases}$$

If our prior beliefs concerning $\mu$ and $\Sigma$ are represented by $f(\mu, \Sigma)$ then the posterior density is

$$f(\mu, \Sigma|y) \propto f(\mu, \Sigma) \prod_{i=1}^I P(Y_i = y_i|\mu, \Sigma),$$

where $y = (y_1, \ldots, y_I)$. This posterior is not only analytically intractable, due to the form the likelihood takes, but it is also very computationally intensive to sample from. Including $Z_i$ in the posterior as a nuisance parameter allows us to write

$$f(\mu, \Sigma, Z|y) \propto f(\mu, \Sigma) \prod_{i=1}^I f(Z_i|\mu, \Sigma) P(Y_i = y_i|Z_i, \mu, \Sigma)$$

$$= f(\mu, \Sigma) \prod_{i=1}^I \left[ f(Z_i|\mu, \Sigma) \prod_{j=1}^J \{I(Z_{ij} \leq 0)I(y_{ij} = 0) + I(Z_{ij} > 0)I(y_{ij} = 1)\} \right],$$

where $Z = (Z_1, \ldots, Z_I)$. This posterior, though still analytically intractable, is now much easier to sample from. The natural choice of distribution for prior knowledge concerning $\mu$ is the multivariate normal, and for $\Sigma$ the inverse Wishart. See appendix B for annotated BUGS code.
Appendix B - BUGS code for implementing multivariate probit model

model{

  # i=1,...,n indexes the number of individuals in the dataset
  # j=1,...,p indexes the number of diseases
  # likelihood

  for(i in 1:n){
    z[i,1:p]~dmnorm(mean[1:p],prec[1:p,1:p])  # z is MVN latent variable
    for(j in 1:p){
      likelihood.j[i,j]<-(step(z[i,j])*y[i,j]+(1-step(z[i,j]))*(1-y[i,j]))
    }
    likelihood[i]<-prod(likelihood.j[i,])
  }  # WinBUGS trick for evaluating non-standard likelihood

  ones[i] <- 1
  ones[i] ~ dbern(likelihood[i])
}

  # priors: MVN prior on the mean vector; Wishart prior on the precision matrix

  mean[1:p]~dmnorm(hyper.prior.mean[1:p],hyper.prior.prec[1:p,1:p])
  prec[1:p,1:p]~dwish(inv.scale[1:p,1:p],df)

  # convert precision matrix to covariance matrix

  cov[1:p,1:p]<-inverse(prec[1:p,1:p])

  # convert covariance matrix to correlation matrix for identifiability

  for(row in 1:p){
    for(col in 1:p){
      Sigma[row,col]<-cov[row,col]/(sqrt(cov[row,row])*sqrt(cov[col,col]))
    }
  }
}

}  # end model